Nov 28 2018
Auris Health is featured in Xconomy for its recent round of fundraising. Auris Health was able to raise an additional $220 million in funding to further bolster its commercialization efforts. Auris received clearance from the FDA to sell the first robotic bronchoscope offered on the Monarch Platform.
Partner Fund Management led this round of funding with new investors that included Wellington Management, D1 Capital Partners and Senator Investment Group and existing investors including Mithril Capital, Lux Capital and Viking Global Investors.
This article further highlighted the robotic technology for endoscopy that uses a flexible scope to access the natural orifices of the body. This cutting-edge technology is designed to enhance the clinicians capabilities when trying to reach and biopsy hard to reach parts of the lung.
The Monarch Platform uses a unique game like controller to navigate the flexible scope deep into the body. This controller combined with robotic technology is designed to enable physicians to steer an endoscope with greater precision.
This recent round of funding is targeted to support the company's fulll commercialization of the Monarch Platform.Read the full article about Auris Health
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.